Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;54(10):e14270.
doi: 10.1111/eci.14270. Epub 2024 Jul 17.

[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis

Raffaella Cassano Cassano  1 , Dario Genovesi  2 , Giuseppe Vergaro  3   4 , Assuero Giorgetti  2 , Alberto Aimo  3   4 , Maria Livia Del Giudice  1 , Sara Galimberti  1 , Michele Emdin  3   4 , Gabriele Buda  1
Affiliations

[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis

Raffaella Cassano Cassano et al. Eur J Clin Invest. 2024 Oct.

Abstract

Often differential diagnosis between AL and ATTR amyloidosis is difficult. Concerning ATTR, sensitive diagnostic tool, as diphosphonate scintigraphy, was validated, instead of no imaging approach is as accurate in AL. Cardiac ultrasound and circulating biomarkers may raise the clinical suspicion but biopsy remains the only option for diagnosis. We aimed to explore the sensitivity of 18F-Florbetaben PET respect to blood tests or periumbilical fat (POF), cardiac, bone marrow (BM) or other tissues biopsies in a cohort of 33 patients.

Keywords: PET/CT imaging; [18F]‐florbetaben PET/TC; amyloid; amyloidosis; free light chains; haematology.

PubMed Disclaimer

References

REFERENCES

    1. Gertz MA . Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022;97(6):818‐829. doi:10.1002/ajh.26569
    1. Palladini G , Milani P , Merlini G . Management of AL amyloidosis in 2020. Hematology Am Soc Hematol Educ Program. 2020;2020(1):363‐371. doi:10.1182/hematology.2020006913
    1. Paiva B , Vıdriales MB , Perez JJ , et al. The clinical utility andprognostic value of multiparameter flow cytom‐etry immunophenotyping in light‐chain amyloi‐dosis. Blood. 2011;117:3613‐3616.
    1. Hosch W , Bock M , Libicher M , et al. MR‐relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Investig Radiol. 2007;42(9):636‐642. doi:10.1097/RLI.0b013e318059e021
    1. Rapezzi C , Quarta CC , Guidalotti PL , et al. Usefulness and limitations of 99mTc‐3,3‐diphosphono‐1,2‐propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470‐478. doi:10.1007/s00259-010-1642-7

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources